References

1. Rich, A. R. (1934). On the frequency of occurrence of occult carcinoma of the prostate. J. Urol. 33, 215-223.

2. De Marzo, A. M., Putzi, M. J., and Nelson, W. G. (2001). New concepts in the pathology of prostatic epithelial carcinogenesis. Urology 57, 103-114.

3. Nelson, W. G., De Marzo, A. M., and Isaacs, W. B. (2003). Prostate cancer. N. Engl. J. Med. 349, 366-381.

4. De Marzo, A. M., DeWeese, T. L., Platz, E. A., et al. (2004). Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J. Cell Biochem. 91, 459-477.

5. Platz, E. A. and De Marzo, A. M. (2004). Epidemiology of inflammation and prostate cancer. J. Urol. 171, S36-S40.

6. Lucia, M. S. and Torkko, K. C. (2004). Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J. Urol. 171, S30-S34; discussion S35.

7. Palapattu, G. S., Sutcliffe, S., Bastian, P. J., et al. (2005). Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26, 1170-1181.

8. Sutcliffe, S. and Platz, E. A. (2006). Inflammation in the etiology of prostate cancer: an epidemiologic perspective. Urologic Oncology: Seminars and Original Investigations, in press.

9. Franks, L. M. (1954). Atrophy and hyperplasia in the prostate proper. J. Pathol. Bacteriol. 68, 617-621.

10. Cheville, J. C. and Bostwick, D. G. (1995). Postatrophic hyperplasia of the prostate. A histologic mimic of prostatic adenocarcinoma. Am. J. Surg. Pathol. 19, 1068-1076.

11. Ruska, K. M., Sauvageot, J., and Epstein, J. I. (1998). Histology and cellular kinetics of prostatic atrophy. Am. J. Surg. Pathol. 22, 1073-1077.

12. Tsujimoto, Y., Takayama, H., Nonomura, N., Okuyama, A., and Aozasa, K. (2002). Postatrophic hyperplasia of the prostate in Japan: histologic and immunohistochemical features and p53 gene mutation analysis. Prostate 52, 279-287.

13. Srigley, J. R. (1988). Small-acinar patterns in the prostate gland with emphasis on atypical adenomatous hyperplasia and small-acinar carcinoma. Semin. Diagn. Pathol. 5, 254-272.

14. Srigley, J. R. (2004). Benign mimickers of prostatic adenocarcinoma. Mod. Pathol. 17, 328-348.

15. Amin, M. B., Tamboli, P., Varma, M., and Srigley, J. R. (1999). Postatrophic hyperplasia of the prostate gland: a detailed analysis of its morphology in needle biopsy specimens. Am. J. Surg. Pathol. 23, 925-931.

16. Oppenheimer, J. R., Wills, M. L., and Epstein, J. I. (1998). Partial atrophy in prostate needle cores: another diagnostic pitfall for the surgical pathologist. Am. J. Surg. Pathol. 22, 440-445.

17. De Marzo, A. M., Platz, E. A., Epstein, J. I., et al. (2006). A working group classification of focal prostate atrophy lesions, Am. J. Surg. Pathol. 30,1281-1291.

18. McNeal, J. E. (1997). Prostate. In Histology for Pathologists, 2nd ed. (Sternberg, S. S., ed.), Lippincott-Raven, Philadelphia, PA, pp. 997-1017.

19. Cohen, R. J., Fujiwara, K., Holland, J. W., and McNeal, J. E. (2001). Polyamines in prostatic epithelial cells and adenocarcinoma; the effects of androgen blockade. Prostate 49, 278-284.

20. Cohen, R. J., McNeal, J. E., Edgar, S. G., Robertson, T., and Dawkins, H. J. (1998). Characterization of cytoplasmic secretory granules (PSG), in prostatic epithelium and their transformation-induced loss in dysplasia and adenocarcinoma. Hum. Pathol. 29, 1488-1494.

21. Bonkhoff, H., Stein, U., and Remberger, K. (1995). Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells [see comments]. Hum. Pathol. 26, 167-170.

22. Cohen, R. J., Glezerson, G., Taylor, L. F., Grundle, H. A., and Naude, J. H. (1993). The neuroendocrine cell population of the human prostate gland. J. Urol. 150, 365-368.

23. Abrahamsson, P. A. (1999). Neuroendocrine cells in tumour growth of the prostate. Endocr. Relat. Cancer 6, 503-519.

24. Epstein, J. I. and Yang, X. J. (2002). Prostate Biopsy Interpretation, 3rd ed. Biopsy interpretation series, Lippincott Williams & Wilkins, Philadelphia, PA.

25. van Leenders, G. J., Gage, W. R., Hicks, J. L., et al. (2003). Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am. J. Pathol. 162, 1529-1537.

26. Parsons, J. K., Gage, W. R., Nelson, W. G., and De Marzo, A. M. (2001). p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 58, 619-624.

27. Billis, A. (1998). Prostatic atrophy: an autopsy study of a histologic mimic of adenocarcinoma. Mod. Pathol. 11, 47-54.

28. McNeal, J. E. (1988). Normal histology of the prostate. Am. J. Surg. Pathol. 12, 619-633.

29. Bennett, B. D., Richardson, P. H., and Gardner, W. A. (1993). Histopathology and cytology of prostatitis. In Prostate Diseases (Lepor, H. and Lawson, R. K., eds.), W.B. Saunders Co., Philadelphia, PA, pp. 399-414.

30. McNeal, J. E. (1988). Normal histology of the prostate. Am. J. Surg. Pathol. 12, 619-633.

31. Liavag, I. (1968). Mitotic activity of prostatic epithelium. A study by means of Colcemid. Acta Pathol. Microbiol. Scand. 73, 19-28.

32. Feneley, M. R., Young, M. P., Chinyama, C., Kirby, R. S., and Parkinson, M. C. (1996). Ki-67 expression in early prostate cancer and associated pathological lesions. J. Clin. Pathol. 49, 741-748.

33. De Marzo, A. M., Marchi, V. L., Epstein, J. I., and Nelson, W. G. (1999). Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 155, 1985-1992.

34. Shah, R., Mucci, N. R., Amin, A., Macoska, J. A., and Rubin, M. A. (2001). Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am. J. Pathol. 158, 1767-1773.

35. Wang, W., Bergh, A., and Damber, J. E. (2004). Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61, 60-72.

36. Faith, D., Han, S., Lee, D. K., et al. (2005). p16 Is upregulated in proliferative inflammatory atrophy of the prostate. Prostate 65, 73-82.

37. McNeal, J. E. (1965). Morphogenesis of prostatic carcinoma. Cancer 18, 1659-1666.

38. Blumenfeld, W., Tucci, S., and Narayan, P. (1992). Incidental lymphocytic prostatitis. Selective involvement with nonmalignant glands. Am. J. Surg. Pathol. 16, 975-981.

39. Liavag, I. (1968). Atrophy and regeneration in the pathogenesis of prostatic carcinoma. Acta Path. Microbiol. Scandinav. 73, 338-350.

40. Gardner, W. A., Jr. and Culberson, D. E. (1987). Atrophy and proliferation in the young adult prostate. J. Urol. 137, 53-56.

41. Murphy, W. M., Soloway, M. S., and Barrows, G. H. (1991). Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68, 821-828.

42. Tetu, B., Srigley, J. R., Boivin, J. C., et al. (1991). Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am.

43. Civantos, F., Marcial, M. A., Banks, E. R., et al. (1995). Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 75, 1634-1641.

44. Reuter, V. E. (1997). Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49, 16-22.

45. Montironi, R. and Schulman, C. C. (1998). Pathological changes in prostate lesions after androgen manipulation.

46. Bostwick, D. G., Qian, J., Civantos, F., Roehrborn, C. G., and Montironi, R. (2004). Does finasteride alter the pathology of the prostate and cancer grading? Clin. Prostate Cancer 2, 228-235.

47. Pomante, R., Santinelli, A., Muzzonigro, G., and Montironi, R. (1999). Nodular hyperplasia of the prostate. Quantitative evaluation of secretory cell changes after treatment with finasteride. Anal. Quant. Cytol. Histol. 21, 63-69.

48. Montironi, R., Mazzucchelli, R., Pomante, R., et al. (1999). Immunohistochemical expression of pi class glutathione S-transferase in the basal cell layer of benign prostate tissue following chronic treatment with finasteride. J. Clin. Pathol. 52, 350-354.

49. Iczkowski, K. A., Qiu, J., Qian, J., et al. (2005). The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 65, 76-82.

50. McNeal, J. E. (1968). Regional morphology and pathology of the prostate. Am.. J. Clin. Pathol. 49, 347-357.

51. McNeal, J. E. (1984). Ageing and the prostate. In Urology in the Elderly (Brocklehurst, J. C., ed.), Churchill Livingstone, Edinburgh, UK, pp. 193-202.

52. Bostwick, D. G., de la Roza, G., Dundore, P., Corica, F. A., and Iczkowski, K. A. (2003). Intraepithelial and stromal lymphocytes in the normal human prostate. Prostate 55, 187-193.

53. Liu, A. Y. and True, L. D. (2002). Characterization of prostate cell types by CD cell surface molecules. Am. J. Pathol. 160, 37-43.

54. Shimura, S., Yang, G., Ebara, S., Wheeler, T. M., Frolov, A., and Thompson, T. C. (2000). Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 60, 5857-5861.

55. Gerstenbluth, R. E., Seftel, A. D., MacLennan, G. T., et al. (2002). Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J. Urol. 167, 2267-2270.

56. Nickel, J. C., Downey, J., Young, I., and Boag, S. (1999). Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 84, 976-981.

57. Schatteman, P. H., Hoekx, L., Wyndaele, J. J., Jeuris, W., and Van Marck, E. (2000). Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur. Urol. 37, 404-412.

58. Nickel, J. C., True, L. D., Krieger, J. N., Berger, R. E., Boag, A. H., and Young, I. D. (2001). Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int. 87, 797-805.

59. Boag, A. H., and Young, I. D. (1999). Pathology of acute and chronic prostate inflammation. In Textbook of prostatitis (Nickel, J. C., ed.). Isis Medical Media Ltd., Oxford, UK, pp. 57-68.

60. Epstein, J. I. and Hutchins, G. M. (1984). Granulomatous prostatitis: distinction among allergic, nonspecific, and posttransurethral resection lesions. Hum. Pathol. 15, 818-825.

61. Macoska, J. A., Trybus, T. M., and Wojno, K. J. (2000). 8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer. Urology 55, 776-782.

62. Tsujimoto, Y., Takakuwa, T., Takayama, H., et al. (2004). In situ shortening of CAG repeat length within the androgen receptor gene in prostatic cancer and its possible precursors. Prostate 58, 283-290.

63. Nakayama, M., Bennett, C. J., Hicks, J. L., et al. (2003). Hypermethylation of the human GSTP1 CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using Laser-Capture Microdissection. Am. J. Pathol. 163, 923-933.

64. Das, D., Shah, R. B., and Imperiale, M. J. (2004). Detection and expression of human BK virus sequences in neoplastic prostate tissues. Oncogene 23, 7031-7046.

65. Bonkhoff, H. and Remberger, K. (1996). Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28, 98-106.

66. De Marzo, A. M., Nelson, W. G., Meeker, A. K., and Coffey, D. S. (1998). Stem cell features of benign and malignant prostate epithelial cells. J. Urol. 160, 2381-2392.

67. van Leenders, G. J. and Schalken, J. A. (2001). Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. BJU Int 88(Suppl. 2), 35-42; discussion 49-50.

68. Litvinov, I. V., De Marzo, A. M., and Isaacs, J. T. (2003). Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J. Clin. Endocrinol. Metab. 88, 2972-2982.

69. van Leenders, G., Dijkman, H., Hulsbergen-van de Kaa, C., Ruiter, D., and Schalken, J. (2000). Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab. Invest. 80, 1251-1258.

70. Yang, Y., Hao, J., Liu, X., Dalkin, B., and Nagle, R. B. (1997). Differential expression of cytokeratin mRNA and protein in normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma. Am. J. Pathol. 150, 693-704.

71. Peehl, D. M., Sellers, R. G., and McNeal, J. E. (1996). Keratin 19 in the adult human prostate: tissue and cell culture studies. Cell Tissue Res. 285, 171-176.

72. Bennett, C. J., Hicks, J. L., Gage, W. R., and De Marzo, A. M. (2003). "False positive" immunostaining for 34BE12 in prostate cancer: Systematic study of the effect of antigen retrieval conditions using high density tissue microarrays. Mod. Pathol. 16, 141A-142A.

73. Gown, A. M. and Vogel, A. M. (1984). Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues. Am. J. Pathol. 114, 309-321.

74. Knudsen, B. S., Lucas, J. M., Fazli, L., et al. (2005). Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am. J. Pathol. 167, 255-266.

75. Bonkhoff, H., Stein, U., and Remberger, K. (1994). The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24, 114-118.

76. McNeal, J. E., Haillot, O., and Yemoto, C. (1995). Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. Prostate 27, 258-268.

77. Ohlson, N., Wikstrom, P., Stattin, P., and Bergh, A. (2005). Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 62, 307-315.

78. van der Kwast, T. H., Tetu, B., Suburu, E. R., Gomez, J., Lemay, M., and Labrie, F. (1998). Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. J. Pathol. 186, 406-409.

79. Bowen, C., Bubendorf, L., Voeller, H. J., et al. (2000). Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression [In Process Citation]. Cancer Res. 60, 6111-6115.

80. Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., et al. (1999). Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13, 966-977.

81. Xu, L. L., Srikantan, V., Sesterhenn, I. A., et al. (2000). Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J. Urol. 163, 972-979.

82. Ornstein, D. K., Cinquanta, M., Weiler, S., et al. (2001). Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. J. Urol. 165, 1329-1334.

83. Korkmaz, C. G., Korkmaz, K. S., Manola, J., et al. (2004). Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis. J. Urol. 172, 1134-1139.

84. Douglas, C., Gage, W. R., Bieberich, C. J., and De Marzo, A. M. (2006). Decreased nkx 3.1 protein expression in atrophy, high grade PIN and adenocarcinoma of the prostate association with Gleason Score and Chromosome 8p deletion. Cancer Res. 66, 10,683-10,690.

85. Guo, Y. P., Sklar, G. N., Borkowski, A., and Kyprianou, N. (1997). Loss of the cyclin-dependent kinase inhibitor P27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin. Cancer Res. 3, 2269-2274.

86. De Marzo, A. M., Meeker, A. K., Epstein, J. I., and Coffey, D. S. (1998). Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am. J. Pathol. 153, 911-919.

87. Cheville, J. C., Lloyd, R. V., Sebo, T. J., et al. (1998). Expression of p27kip1 in prostatic adenocarcinoma. Mod. Pathol. 11, 324-328.

88. Cordon-Cardo, C., Koff, A., Drobnjak, M., et al. (1998). Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl. Cancer Inst. 90, 1284-1291.

89. Cote, R. J., Shi, Y., Groshen, S., et al. (1998). Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J. Natl. Cancer Inst. 90, 916-920.

90. Fernandez, P. L., Arce, Y., Farre, X., et al. (1999). Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J. Pathol. 187, 563-566.

91. Tsihlias, J., Kapusta, L. R., DeBoer, G., et al. (1998). Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58, 542-548.

92. Yang, R. M., Naitoh, J., Murphy, M., et al. (1998). Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 159, 941-945.

93. Garraway, L. A., Lin, D., Signoretti, S., et al. (2003). Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate 55, 206-218.

94. Cookson, M. S., Reuter, V. E., Linkov, I., and Fair, W. R. (1997). Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J. Urol. 157, 673-676.

95. Lee, W. H., Morton, R. A., Epstein, J. I., et al (1994). Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91, 11,73311,737.

96. Moskaluk, C. A., Duray, P. H., Cowan, K. H., Linehan, M., and Merino, M. J. (1997). Immunohistochemical expression of pi-class glutathione S-transferase is down-regulated in adenocarcinoma of the prostate. Cancer 79, 1595-1599.

97. Parsons, J. K., Nelson, C. P., Gage, W. R., Nelson, W. G., Kensler, T. W., and De Marzo, A. M. (2001). GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate 49, 30-37.

98. Zha, S., Gage, W. R., Sauvageot, J., et al. (2001). Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 61, 8617-8623.

99. Naslund, M. J., Strandberg, J. D., and Coffey, D. S. (1988). The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J. Urol. 140, 1049-1053.

100. Sharma, O. P., Adlercreutz, H., Strandberg, J. D., Zirkin, B. R., Coffey, D. S., and Ewing, L. L. (1992). Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J. SteroidBiochem. Mol. Biol. 43, 557-564.

101. Prins, G. S. (1992). Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinology 130, 2401-2412.

102. Billis, A. and Magna, L. A. (2003). Inflammatory atrophy of the prostate. Prevalence and significance. Arch. Pathol. Lab. Med. 127, 840-844.

Was this article helpful?

0 0

Post a comment